open access

Vol 27, No 2 (2022)
Research paper
Early publication date: 2022-02-08
Get Citation

The utility of 18F-FDG PET/CT in brain tumours diagnosis

Agata Pietrzak12, Andrzej Marszałek3, Tomasz Piotrowski14, Katarzyna Pietrasz2, Adrianna Medak5, Julia Wojtowicz6, Hubert Szweda4, Krzysztof Matuszewski4, Witold Cholewiński21
DOI: 10.5603/RPOR.a2022.0021
·
Rep Pract Oncol Radiother 2022;27(2):235-240.
Affiliations
  1. Electroradiology Department, Poznan University of Medical Sciences, Poznan, Poland
  2. Nuclear Medicine Department, Greater Poland Cancer Centre, Poznan, Poland
  3. Chair of Oncologic Pathology and Prophylaxis Poznan University of Medical Sciences and the Greater Poland Cancer Centre, Poznan, Poland
  4. Medical Physics Department, Greater Poland Cancer Centre, Poznan, Poland
  5. Electroradiology Department, Poznan University of Medical Sciences, Poznan, Poland (student)
  6. Medical Faculty, Lodz Medical University, Lodz, Poland (student)

open access

Vol 27, No 2 (2022)
Original research articles
Early publication date: 2022-02-08

Abstract

Background: The purpose of the study was to discuss whether 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) study protocol should include brain imaging.

Materials and methods: Analysis of international societies recommendations compared with the original data obtained in over 1000 consecutive torso and brain 18F-FDG PET/CT studies collected in 2010.

Results: According to the international societies recommendations, the 18F-FDG should not be the radiotracer of choice considering the brain region PET/CT study. However, it can be performed as an additional brain imaging tool. Based on at least a 3-year follow-up, we detected 8 cases of suspicious brain findings and no primary lesion among over 1000 consecutive torso and brain 18F-FDG PET/CT scans performed in 2010. However, in 5 out of 8 patients, the brain lesion was the only metastasis detected, affecting further therapy.

Conclusions: The 18F-FDG PET/CT study may help detect malignant brain lesions and, therefore, including brain region imaging into the study protocol should be considered. 

Abstract

Background: The purpose of the study was to discuss whether 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) study protocol should include brain imaging.

Materials and methods: Analysis of international societies recommendations compared with the original data obtained in over 1000 consecutive torso and brain 18F-FDG PET/CT studies collected in 2010.

Results: According to the international societies recommendations, the 18F-FDG should not be the radiotracer of choice considering the brain region PET/CT study. However, it can be performed as an additional brain imaging tool. Based on at least a 3-year follow-up, we detected 8 cases of suspicious brain findings and no primary lesion among over 1000 consecutive torso and brain 18F-FDG PET/CT scans performed in 2010. However, in 5 out of 8 patients, the brain lesion was the only metastasis detected, affecting further therapy.

Conclusions: The 18F-FDG PET/CT study may help detect malignant brain lesions and, therefore, including brain region imaging into the study protocol should be considered. 

Get Citation

Keywords

brain tumour; 18F-fluorodeoxyglucose; oncology

About this article
Title

The utility of 18F-FDG PET/CT in brain tumours diagnosis

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 27, No 2 (2022)

Article type

Research paper

Pages

235-240

Early publication date

2022-02-08

Page views

912

Article views/downloads

53

DOI

10.5603/RPOR.a2022.0021

Bibliographic record

Rep Pract Oncol Radiother 2022;27(2):235-240.

Keywords

brain tumour
18F-fluorodeoxyglucose
oncology

Authors

Agata Pietrzak
Andrzej Marszałek
Tomasz Piotrowski
Katarzyna Pietrasz
Adrianna Medak
Julia Wojtowicz
Hubert Szweda
Krzysztof Matuszewski
Witold Cholewiński

References (24)
  1. Stewart BW, Wild CP. World Cancer Report 2014. International Agency for Research on Cancer, Lyon 2014: 511–520.
  2. McClelland Iii S, Agrawal N, Elbanna MF, et al. Baseline Karnofsky performance status is independently predictive of death within 30 days of intracranial radiation therapy completion for metastatic disease. Rep Pract Oncol Radiother. 2020; 25(4): 698–700.
  3. Nieder C, Hintz M, Popp I, et al. Long-term survival results after treatment for oligometastatic brain disease. Rep Pract Oncol Radiother. 2020; 25(3): 307–311.
  4. Newton: National Brain Tumor Society; c2021. braintumor.org (2021 Apr 16).
  5. Lin YJ, Chiu HY, Chiou MJ, et al. Trends in the incidence of primary malignant brain tumors in Taiwan and correlation with comorbidities: A population-based study. Clin Neurol Neurosurg. 2017; 159: 72–82.
  6. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006; 47(5): 885–895 [Erratum in J Nucl Med 2006;47:903].
  7. Waxman AD, Herholz K, Lewis DH, Herscovitch P, Minoshima S, Ichise M. Society of Nuclear Medicine Procedure Guideline for FDG PET Brain Imaging Version 1.0. Society of Nuclear Medicine, Reston 2009.
  8. Albano D, Bosio G, Bertoli M, et al. 18F-FDG PET/CT in primary brain lymphoma. J Neurooncol. 2018; 136(3): 577–583.
  9. Vojtíšek R, Ferda J, Fínek J. Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy. Rep Pract Oncol Radiother. 2015; 20(3): 210–216.
  10. Purandare NC. Inclusion of brain in FDG PET/CT scanning techniques in cancer patients: Does it obviate the need for dedicated brain imaging? Indian J Nucl Med. 2011; 26(2): 64–66.
  11. Huston SF, Abdelmalik AG, Nguyen NC, et al. Whole-body 18F-FDG PET/CT: the need for a standardized field of view--a referring-physician aid. J Nucl Med Technol. 2010; 38(3): 123–127.
  12. Tasdemir B, Dostbil Z, Inal A, et al. Evaluation of clinical contributions provided by addition of the brain, calvarium, and scalp to the limited whole body imaging area in FDG-PET/CT tumor imaging. Biomed Res Int. 2014; 2014: 129683.
  13. Fonti R, Pellegrino S, Mainolfi CG, et al. Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma. Diagnostics (Basel). 2020; 10(6).
  14. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2): 328–354.
  15. Varrone A, Asenbaum S, Vander Borght T, et al. European Association of Nuclear Medicine Neuroimaging Committee. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009; 36(12): 2103–2110.
  16. International Atomic Energy Agency. Standard Operating Procedures for PET/CT: A Practical Approach for Use in Adult Oncology, IAEA Human Health Series No. 26. IAEA, Vienna 2013.
  17. Testanera G, Pee G. Imaging in Oncological Brain Diseases: PET/CT. In: Costa PF, Santos S, Vidovič B. ed. Brain Imaging A Technologist's Guide. EANM, Vienna 2015: 33–53.
  18. Socan A. Tracers for Brain Imaging. In: Costa CF, Santos A, Vidovič B. ed. Brain Imaging. A Technologist's Guide. EANM, Vienna 2015: 12–25.
  19. Jung JiH, Ahn BC. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat. 2018; 6(2): 47–53.
  20. Baldi D, Tramontano L, Alfano V, et al. Whole Body Low Dose Computed Tomography Using Third-Generation Dual-Source Multidetector With Spectral Shaping: Protocol Optimization and Literature Review. Dose Response. 2020; 18(4): 1559325820973131.
  21. Nakayama M, Okizaki A, Ishitoya S, et al. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med. 2013; 27(2): 163–169.
  22. Galldiks N, Langen KJ, Albert NL, et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. Neuro Oncol. 2019; 21(5): 585–595.
  23. Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019; 16(8): 509–520.
  24. Bochev P, Klisarova A, Kaprelyan A, et al. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Hell J Nucl Med. 2012; 15(2): 125–129.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl